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A deep learning system accurately classifies
primary and metastatic cancers using passenger
mutation patterns
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In cancer, the primary tumour’s organ of origin and histopathology are the strongest deter-
minants of its clinical behaviour, but in 3% of cases a patient presents with a metastatic
tumour and no obvious primary. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole
Genomes (PCAWG) Consortium, we train a deep learning classifier to predict cancer type
based on patterns of somatic passenger mutations detected in whole genome sequencing
(WGS) of 2606 tumours representing 24 common cancer types produced by the PCAWG
Consortium. Our classifier achieves an accuracy of 91% on held-out tumor samples and 88%
and 83% respectively on independent primary and metastatic samples, roughly double the
accuracy of trained pathologists when presented with a metastatic tumour without knowl-
edge of the primary. Surprisingly, adding information on driver mutations reduced accuracy.
Our results have clinical applicability, underscore how patterns of somatic passenger
mutations encode the state of the cell of origin, and can inform future strategies to detect the
source of circulating tumour DNA.
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Human cancers are distinguished by their anatomic organ oforigin and their histopathology. For example, squamous cellcarcinoma originates in the lung and has a histology similar
to the normal squamous epithelium that lines bronchi and
bronchioles. Together these two criteria, which jointly reflect the
tumour’s cell of origin, are the single major predictor of the natural
history of the disease, including the age at which the tumour
manifests, its factors, growth rate, pattern of invasion and metas-
tasis, response to therapy and overall prognosis. Studies have shown
that site-directed therapy based on the tumour’s cell of origin is
more effective than broad-spectrum chemotherapy1. However, it is
not always straightforward to determine the origin of a metastatic
tumour. In the most extreme case, a clinician may be presented with
the challenge of determining the source of a poorly differentiated
metastatic cancer when multiple imaging studies have failed to
identify the primary (‘cancer of unknown primary,’ CUPS)2. In
current clinical practice, pathologists use histological criteria assis-
ted by immunohistochemical stains to determine such tumours’
histological type and site of origin3, but this process can be complex
and time-consuming, and some tumours are so poorly differ-
entiated that they no longer express the cell-type-specific proteins
needed for unambiguous immunohistochemical classification.
Based on recent large-scale exome and genome-sequencing
studies, we know that major tumour types present different pat-
terns of somatic mutation4–7. For example, ovarian cancers are
distinguished by a high rate of genomic rearrangements8, chronic
myelogenous leukaemias (CML) carry a nearly pathognomonic
structural variation involving a t(9;22) translocation leading to a
BCR–ABL fusion transcript9, melanomas have high rates of C > T
and G > A transition mutations due to UV damage10 and pan-
creatic ductal adenocarcinomas have near-universal activating
mutations in the KRAS gene11. Recent work has pointed to a
strong correlation between the regional somatic mutation rate and
chromatin accessibility as measured by DNase I sensitivity and
histone mark12, and has suggested that the cell of origin can be
inferred from regional mutation counts13.
The PCAWG Consortium aggregated whole-genome-sequencing
data from 2658 cancers across 38 tumour types generated by the
ICGC and TCGA projects. These sequencing data were re-analysed
with standardised, high-accuracy pipelines to align to the human
genome (reference build hs37d5) and identify germline variants and
somatically acquired mutations, as described in the PCAWG
Network7.
This paper asks whether we can use machine-learning techni-
ques to accurately determine tumour organ of origin and histology
using the patterns of somatic mutation identified by whole-
genome DNA sequencing. One motivation of this effort was to
demonstrate the feasibility of a next-generation sequencing
(NGS)-based diagnostic tool for tumour-type identification. Due
to its stability, DNA is particularly easy to recover from fresh and
historical tumour samples; furthermore, because mutations accu-
mulate in DNA, they form a historic record of tumour evolution
unaffected by the local, metastatic environment. Here we use
deep-learning techniques to explore whether a simple DNA-based
sequencing and analysis protocol for tumour-type determination
would be a useful adjunct to existing histopathological techniques.
Unexpectedly, we find that passenger mutation regional dis-
tribution and mutation type are sufficient to discriminate among
tumour types with a high degree of accuracy, while driver genes
and pathways contribute and provide no improvement to the
classifier.
Results
Training set. Using the Pan-cancer Analysis of Whole Genomes
(PCAWG) data set7, we built a series of tumour-type classifiers
using individual sequence-based features and combinations of
features. The best-performing classifier was validated against an
independent set of tumour genomes to determine overall pre-
dictive accuracy, and then tested against a series of metastatic
tumours from known primaries to determine the accuracy of
predicting the primary from a metastasis.
The full PCAWG data set consists of tumours from 2778 donors
comprising 34 main histopathological tumour types, uniformly
analysed using the same computational pipeline for quality-control
filtering, alignment and somatic mutation calling. However, the
PCAWG tumour types are unevenly represented, and several have
inadequate numbers of specimens to adequately train and test a
classifier. We chose a minimum cut-off of 35 donors per tumour
type. In a small number of cases, the same donor contributed both
primary and metastatic tumour specimens to the PCAWG data set.
In these cases, we used only the primary tumour for training and
evaluation, except for the case of the small cohort of myelopro-
liferative neoplasms (Myeloid-MPN; N= 55 samples), for which
multiple primary samples were available. In this case, we used up to
two samples per donor and partitioned the training and testing sets
to avoid having the same donor appear more than once in
any training/testing set trial. The resulting training set consisted of
2436 tumours spanning 24 major types (Table 1; Supplementary
Data 1).
Classification using single-mutation feature types. To deter-
mine the predictive value of different mutation features, we
trained and evaluated a series of tumour-type classifiers based on
single categories of feature derived from the tumour mutation
profile. For each feature category we developed a random forest
(RF) classifier (see the Methods section). Each classifier’s input
was the mutational feature profile for an individual tumour
specimen, and its output was the probability estimate that the
specimen belongs to the type under consideration. Each classifier
was trained using a randomly selected set of 75% of samples
drawn from the corresponding tumour type. To determine the
most likely type for a particular tumour sample, we applied its
mutational profile to each of the 24 type-specific classifiers, and
selected the type whose classifier emitted the highest probability.
To evaluate the performance of the system, we applied stratified
fourfold cross-validation by training on three-quarters of the data
set and testing against each of the other-quarter specimens. We
report overall accuracy as well as recall, precision and the F1 score
using the average of all four test data sets (see the ‘Methods'
section for cross-validation methodology and definitions of
terms).
We selected a total of seven mutational feature types spanning
three major categories (Table 2):
We assessed mutation distribution. The somatic mutation rate
in cancers varies considerably from one region of the genome to
the next5. In whole-genome sequencing, a major covariate of this
regional variation in whole-genome sequences is the epigenetic
state of the tumour’s cell of origin, with 74–86% of the variance in
the mutation density being explained by histone marks and other
chromatin features related to open versus closed chromatin6. This
suggests that tumours sharing similar cells of origin will have a
similar topological distribution of mutations across the genome.
To capture this, we divided the genome into ~3000 1-Mbp bins
across the autosomes (excluding sex chromosomes) and created
features corresponding to the number of somatic mutations per
bin normalised to the total number of somatic mutations.
Mutation rate profiles were created independently for somatic
substitutions (SNV), indels, somatic copy-number alterations
(CNA) and other structural variations (SV). Note that the vast
majority of variants, e.g., at least 99% of the SNVs in nearly all
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samples, used for this analysis are non-functional passenger
mutations. See Campbell7 and Li14 for descriptions of point and
structural variations in the PCAWG data set.
We also assessed mutation type. The type of the mutation and
its nucleotide neighbours, for example G{C > T}C, is an indicator
of the exposure history of the cell of origin to extrinsic and
endogenous factors that promote mutational processes15. This in
turn can provide information on the aetiology of the tumour. For
example, skin cancers have mutation types strongly correlated
with UV light-induced DNA damage. Reasoning that similar
tumour types will have similar mutational exposure profiles, we
generated a series of features that represented the normalised
frequencies of each potential nucleotide change in the context of
its 5′ and 3′ neighbours. Like the mutation distribution, the
variants that contribute to this feature category are mostly
passengers. Readers are referred to Alexandrov16 for more
information on signature analysis in the PCAWG data set.
Finally, we assessed driver genes/pathways. Some tumour types
are distinguished by high frequencies of alterations, in particular
driver genes and pathways. For example, melanomas have a high
frequency of BRAF gene mutations17, while pancreatic cancers
are distinguished by KRAS mutations11. We captured this in two
ways: (1) whether a gene is affected by a driver event as
determined by the PCAWG Cancer Drivers Working Group18,
and (2) whether there was an impactful coding mutation in any
gene belonging to a known or suspected driver pathway (also see
Reyna19 for cancer pathway analysis performed by the PCAWG
Pathway and Networks Working Group). We counted driver
events affecting protein-coding genes, long non-coding RNAs and
micro-RNAs, but did not attempt to account for alterations in cis-
regulatory regions. In all we created ~2000 driver pathway-related
features describing potential gene and pathway alterations for
each tumour.
The accuracy of individual RF classifiers ranged widely across
tumour and feature categories, with a median F1 (harmonic mean
of recall and precision) of 0.42 and a range from 0.00 to 0.94
(Fig. 1a, b; Supplementary Fig. 1, Supplementary Data 2). Nine
tumour types had at least one well-performing classifier that
achieved an F1 of 0.80: CNS-GBM, CNS-PiloAstro, Liver-HCC,
Lymph-BNHL, Kidney-RCC, Myeloid-MPN, Panc-AdenoCA,
Table 1 Distribution of tumour types in the PCAWG training and test data sets.
Abbreviation Organ system Tumour type Tumour samples
Liver-HCC Liver Liver hepatocellular carcinoma 306
Panc-AdenoCA Pancreas Pancreatic adenocarcinoma 235
Breast-AdenoCA Breast Breast adenocarcinoma 198
Prost-AdenoCA Prostate gland Prostate adenocarcinoma 189
CNS-Medullo Brain, cranial nerves and spinal cord Medulloblastoma 146
Kidney-RCC Kidney Renal cell carcinoma (proximal tubules) 143
Ovary-AdenoCA Ovary Ovarian adenocarcinoma 112
Skin-Melanoma Skin Skin-melanoma 106
Lymph-BNHL Lymph nodes Mature B-cell lymphoma 105
Eso-AdenoCA Oesophagus Oesophageal adenocarcinoma 98
Lymph-CLL Blood, bone marrow and hematopoietic sysstem Chronic lymphocytic leukaemia 95
CNS-PiloAstro Brain, cranial nerves and spinal cord Pilocytic astrocytoma 89
Panc-Endocrine Pancreas Pancreatic neuroendocrine tumour 85
Stomach-AdenoCA Stomach Gastric adenocarcinoma 70
Head-SCC Gum, floor of mouth and other mouth Head/neck squamous cell carcinoma 57
ColoRect-AdenoCA Large intestine (excluding appendix) Colorectal adenocarcinoma 52
Lung-SCC Lung and bronchus Lung squamous cell carcinoma 48
Thy-AdenoCA Thyroid gland Thyroid adenocarcinoma 48
Myeloid-MPN Blood, bone marrow and hematopoietic system Myeloproliferative neoplasm 46
Kidney-ChRCC Kidney Renal cell carcinoma (distal tubules) 45
Bone-Osteosarc Bones and joints Sarcoma, bone 44
CNS-GBM Brain, cranial nerves and spinal cord Diffuse glioma 41
Uterus-AdenoCA Uterus, nos Uterine adenocarcinoma 40
Lung-AdenoCA Lung and bronchus Lung adenocarcinoma 38
2436
Table 2 WGS feature types used in classifiers.
Feature category Feature type Feature count Description
Mutation distribution SNV-BIN 2897 Number of SNVs per 1-Mbp bin, and per chromosome, normalised against the total number of
SNVs per sample
CNA-BIN 2826 Number of CNAs per 1-Mbp bin
SV-BIN 2929 Number of SVs per 1-Mbp bin, and per chromosome, normalised against the total number of SV
per sample
INDEL-BIN 2757 Number of SNVs per 1-Mbp bin, and per chromosome, normalised against the total number of
INDEL per sample
Mutation type MUT-WGS 150 Type of single-nucleotide substitution, double- and triple-nucleotide substitution (plus its
adjacent nucleotide neighbours)
Driver gene/pathway GEN 554 Presence of an impactful mutation in a suspected driver gene
MOD 1865 Presence of an impactful mutation in a gene belonging to a suspected driver pathway
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Prost-AdenoCA and Skin-melanoma. Five classifiers performed
poorly, with no classifier achieving an accuracy greater than 0.6:
Bone-Osteosarc, Head-SCC, Stomach-AdenoCA, Thy-AdenoCA
and Uterus-AdenoCA. The remaining eight tumour types had
classifiers achieving F1s between 0.60 and 0.80.
The highest accuracies were observed for features related to
mutation type and distribution (Fig. 1b). Contrary to our
expectations, altered driver genes and pathways were poor
discriminatory features. Whereas both SNV type and distribution
achieved median F1 scores of ~0.7, RF models built on driver
gene or pathway features achieved median F1s of 0.33 and 0.27,
respectively. Only Panc-AdenoCA, Kidney-RCC, Lymph-BNHL
and ColoRect-AdenoCA exceeded F1s greater than 0.75 on RF
models built from gene or pathway-related features, but we note
that even in these cases, the mutation type and/or distribution
features performed equally well.
Classification using combinations of mutation feature types.
We next asked whether we could improve classifier accuracy by
combining features from two or more categories. We tested both
Random Forest (RF) and multi-class Deep Learning/Neural
Network (DNN)-based models (Methods), and found that overall
the DNN-based models were more accurate than RF models
across a range of feature category combinations (median F1=
0.86 for RF, F1= 0.90 for DNN, p < 1.2e–7 Wilcoxon Rank Sum
Test; Fig. 1c). For the DNN-based models, overall accuracy was
the highest when just the topological distribution and mutation
type of SNVs were taken into account. Adding gene and/or
pathway features slightly reduced classification accuracy; using
only gene and pathway features greatly reduced classifier per-
formance. We did not investigate the effect of training the DNN
on CNV or SV features as these mutation types were not uni-
formly available in the validation data sets (see below).
Figure 2 shows a heatmap of the DNN classifier accuracy when
tested against held-out tumours (mean of 10 independently built
models). Overall, the accuracy for the complete set of 24 tumour
types was 91% (classification accuracy), but there was consider-
able variation for individual tumours types (Supplementary
Data 3). Recall (also known as sensitivity) ranged from 0.61
(Stomach-AdenoCA) to 0.99 (Kidney-RCC). Precision (similar to
specificity but is sensitive to the number of positives in the data
set) was comparable, with rates ranging from 0.74 (Stomach-
AdenoCA) to 1.00 (CNS-GBM, Skin-Melanoma and Liver-HCC).
Twenty-one of 24 tumour types achieved F1s greater than 0.80,
including 8 of the 9 types that met this threshold for RF models
built on single-feature categories. The three worst-performing
tumour types were CNS-PiloAstro (mean F1 0.79 across 10
independently trained DNN models), Lung-AdenoCA (F1 0.77)
and Stomach-AdenoCA (F1 0.67).
We investigated the effect of the training set size on classifier
accuracy (Fig. 3a). Tumour types with fewer than 100 samples in
the data set were more likely to make incorrect predictions,
and tumour types with large numbers of samples were among the
top performers. However, several tumour types, including
ColoRect-AdenoCA (N= 52), Lung-SCC (N= 48) and CNS-
GBM (N= 41), achieved excellent predictive accuracy despite
having small training sets.
The DNN emits a softmax output that can be interpreted as
the probability distribution of the tumour sample across the
24 cancer types. We ordinarily select the highest-probability
tumour type as the classifier’s choice. If instead we asked how
often the correct type is contained among the top N-ranked
probabilities, we find that the worst-performing tumour type
(Stomach-AdenoCA) achieved a true-positive rate of of 0.88 for
placing the correct tumour type among the top ranked three
choices, and that the average true-positive rate across all tumour
types for this task was 0.98 (Fig. 3b).
Patterns of misclassification. Misclassifications produced by the
DNN in many cases seem to reflect shared biological character-
istics of the tumours. For example, the most frequent classifica-
tion errors for Stomach-AdenoCA samples were to two other
upper gastrointestinal tumours, oesophageal adenocarcinoma
(Eso-AdenoCA, 14% misclassification rate), and pancreatic ductal
adenocarcinoma (Panc-AdenoCA, 9%). These three organs share
a common developmental origin in the embryonic foregut and
may share similar epigenetic profiles. We also speculate that the
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Fig. 1 Comparison of tumour-type classifiers using single and multiple
feature types. a Radar plots describing the cross-validation-derived
accuracy (F1) score of Random Forest classifiers trained on each of 7
individual feature categories, across six representative tumour types.
b Summary of Random Forest classifier accuracy (F1) trained on individual
feature categories across all 24 tumour types. c Accuracy of classifiers
trained on multiple feature categories. RF Best Models corresponds to the
cross-validation F1 scores of Random Forest classifiers trained on the three
best single-feature categories for all 24 tumour types. DNN Model shows
the distribution of F1 scores for held-out samples for a multi-class neural
network trained using passenger mutation distribution and type. DNN
Model+ Drivers shows F1 scores for the neural net when driver genes and
pathways are added to the training features. The centre line in the boxplot
represents the median of the F1 scores. The lower and upper bounds of the
box represent the first and third quartile. The whiskers extend to 1.5 IQR
plus the third quartile or minus the first quantile.
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high rate of confusion between gastric and oesophageal
cancers might be due to similar mutational exposures among the
two sites: a subset of C– > A, C– > G substitutions are commonly
seen in stomach and oesophageal (but not pancreatic) cancers
and comprise Signature 17 in the COSMIC catalogue of muta-
tional signatures20. To test this, we assessed the effect of training
the DNN with mutation distribution alone, excluding mutation-
type features (Supplementary Fig. 2). Using just passenger
mutation distribution, the overall F1 for stomach tumours
increased by 4%, supporting the idea that part of the error is due
to shared mutational signatures among stomach and oesophageal
cancer. Another possible explanation for the frequent mis-
classification of gastric and oesophageal tumours is that some
of the tumours labelled gastric arose at the gastroesophageal
junction (GEJ), which some consider to be a distinct subset of
oesophageal tumours21.
Other common misclassification errors include misclassifica-
tion of 12% of chronic lymphocytic leukaemia (Lymph-CLL)
samples as B-cell non-Hodgkin’s lymphoma (Lymph-BNHL).
Both tumours are derived from the B-cell lymphocyte lineage,
and likely share a similar cell of origin. Another pattern was
occasional misclassifications among the three types of brain
tumour: CNS-GBM, CNS-Medullo and CNS-PiloAstro, all three
of which are derived from various glial lineages. We speculate that
these errors are again due to similarities among the cells of origin
of these tissues.
Of note is that the DNN was able to accurately distinguish
among several tumour types that arise from the same organ.
Renal cell carcinoma (Kidney-RCC) and chromophobe renal
carcinoma (Kidney-ChRCC) were readily distinguished from
each other, as were the squamous and adenocarcinoma forms of
non-small-cell lung cancer (Lung-SCC, Lung-AdenoCA), and the
exocrine and endocrine forms of pancreatic cancer (Panc-
AdenoCA, Panc-Endocrine). The misclassification rate between
Lung-SCC and Lung-AdenoCA was just 8%, and all other pairs
had misclassification rates of 2% or lower. This is in keeping with
a model in which major histological subtypes of tumours reflect
different cells of origin.
Validation on an independent set of primary tumours. A dis-
tinguishing characteristic of the PCAWG data set is its use of a
uniform computational pipeline for sequence alignment, qual-
ity filtering and variant calling. In real-world settings, however,
the data set used to train the classifier may be called using a
different set of algorithms than the test data. To assess the
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accuracy of DNA-based tumour identification when applied in
this setting, we applied the classifier trained on PCAWG sam-
ples to an independent validation set of 1436 cancer whole
genomes assembled from a series of published non-PCAWG
projects. The validation set spans 14 distinct tumour types
assembled from 21 publications or databases (Supplementary
Data 4). We were unable to collect sufficient numbers of
independent tumour genomes representing nine of the 24 types
in the merged classifier, including colorectal cancer, thyroid
adenocarcinoma and lung squamous cell carcinoma. SNV
coordinates were lifted from GRCh38 to GRCh37 when
necessary, but we did not otherwise process the mutation call
sets. With the exception of a set of liver cancer (Liver-HCC)
samples in the validation set, which is discussed below, a
comparison of the mutation load among each tumour-type
cohort revealed no significant differences between the PCAWG
and validation data sets (Supplementary Fig. 3).
The DNN classifier recall for the individual tumour types
included in the validation data set ranged from 0.41 to 0.98, and
the precision ranged from 0.43 to 1.0 (Fig. 4a), achieving an
overall accuracy of 88% for classification across the multiple
types. In general, the tumour types that performed the best
within the PCAWG data set were also the most accurate within
the validation, with Breast-AdenoCA, Ovary-AdenoCA, Panc-
AdenoCA, Lymph-CLL, CNS-Medullo and Kidney-RCC
tumour types all achieving >85% accuracy. The Eso-AdenoCA,
Liver-HCC and Paediatric Gliomas were poorly predicted with
recalls below 70%, and the remaining types had intermediate
accuracies.
The majority of classification errors observed in the primary
tumour validation set mirrored the patterns of misclassifica-
tions previously observed within the PCAWG samples, with the
exception that Liver-HCC cases were frequently misclassified as
CNS-Medullo (13%). We believe this case to be due to a lower-
than-expected mutation burden in the liver tumours from the
validation set (median 3202 SNVs per sample in validation
set vs. 22,230 SNVs per sample in the PCAWG training set;
P < 1.5e–15 by Wilcoxon Rank Sum Test; Supplementary Fig. 3).
This mutation load is more similar to the rates observed in
CNS-Medullo (median 2330 per sample) among the PCAWG
samples, and might suggest poor coverage of Liver-HCC or
another sequencing/analysis artefact in the validation set.
We were initially puzzled that a set of 49 validation data set
samples that were identified as CNS glioma overwhelmingly
matched to the paediatric piloastrocytoma model rather than to
the CNS-GBM model. However, on further investigation, we
discovered that these samples represent a mixture of low- and
high-grade paediatric gliomas, including piloastrocytomas22–24.
The SNV mutation burden of these paediatric gliomas is
also similar to CNS-PiloAstro and significantly lower than adult
CNS-GBM (Supplementary Fig. 3).
Validation on an independent set of metastatic tumours.
To evaluate the ability of the classifier to correctly identify the
type of the primary tumour from a metastatic tumour
sample, we developed an independent validation data set that
combined a published series of 92 metastatic Panc-AdenoCA25
with an unpublished set of 2,028 metastatic tumours from
known primaries across 16 tumour types recently sequenced by
the Hartwig Medical Foundation (HMF)26, resulting in a
combined set of 2120 samples across 16 tumour types (Sup-
plementary Data 4). All metastatic samples were subjected to
paired-end WGS sequencing of tumour and normal at a
tumour coverage of at least 65 × , but the computational pipe-
lines used for alignment, quality filtering and SNV calling were
different from those used for PCAWG. The rules for matching
classifier output to the validation set class labels were developed
in advance of the experiment, and the DNN classifier was
applied to the molecular data from the validation set in a blind
fashion.
When the DNN classifier was applied to these metastatic
samples, it achieved an overall accuracy of 83% for identifying
the type of the known primary (Fig. 4b), which is similar to its
performance on the validation primaries. Seven of the tumour
types in the metastatic set achieved recall rates of 0.80 or
higher, including Breast-AdenoCA (0.97), Kidney (0.96), Panc-
AdenoCA (0.94), Prost-AdenoCA (0.86), Skin-Melanoma
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(0.85), ColoRect-AdenoCA (0.85) and Lung (0.83). On the
other end of the spectrum, four tumour types failed to achieve a
recall of at least 0.50: Head-SCC (0.38), Uterus-AdenoCA
(0.30), Stomach-AdenoCA (0.23) and Thyroid-AdenoCA
(0.08). Overall, the patterns of misclassification were similar
to what was seen within PCAWG. For example, the gastric
cancers were misclassified as oesophageal tumours 53% of
the time.
In contrast to the other tumour types, metastatic thyroid
adenocarcinoma was a clear outlier. In this case, the DNN
was unable to correctly identify a great majority of the 13
metastatic samples, classifying them instead as other tumour
types such as Kidney, Panc-Endocrine, Prost-AdenoCA or
Breast-AdenoCA. We lack information on the histological
subtype of the metastatic thyroid tumours in the HMF data
set, but speculate that the metastatic thyroid tumours in this set
are enriched in more aggressive histological subtypes than the
PCAWG primaries, which are exclusively of low-grade papillary
(N= 31), papillary–follicular (N= 18) and papillary–columnar
(N= 1) types.
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The HMF data set also included 62 CUP tumours. While we do
not know the corresponding primary for these samples, we did
attempt to classify them (Supplementary Data 5). The CUP cases
were most frequently classified as Liver-HCC (N= 10; 16%),
Lung-AdenoCA (N= 9; 15%) and Panc-AdenoCA (N= 8; 13%).
Reassuringly, despite the fact that information on the sex
chromosomes was not used by the classifier, almost all the CUP
tumours classified as gynaecological tumours (Breast-AdenoCA,
N= 5; Uterus-AdenoCA, N= 2) came from female patients,
except one patient with low confident prediction.
Discussion
Cancer of unknown primary site (CUPS) is a heterogeneous set
of cancers diagnosed when a patient presents with metastatic
disease, but despite extensive imaging, pathological and mole-
cular studies of the primary cannot be determined1. CUPS
accounts for 3–5% of cancers, making it the seventh to eighth
most frequent type of cancer and the fourth most common
cause of cancer death27. Even at autopsy, the primary cannot be
identified ~70% of the time28, suggesting regression of the
primary in many CUPS cases. CUPS is a clinical dilemma,
because therapeutic options are largely driven by tissue of
origin, and site-directed therapy is more effective than broad-
spectrum chemotherapy1. A related diagnostic challenge arises,
paradoxically, from the medical community’s success in treat-
ing cancers and the rising incidence of second primary cancers,
now estimated at roughly 16% of incident cancers29. Patholo-
gists are often asked to distinguish a late metastatic recurrence
of a previously treated primary from a new unrelated primary.
However, histopathology alone may be inaccurate at identifying
the site of origin of metastases. In one study30, pathologists who
were blinded to the patient’s clinical history were able to
identify the primary site of a metastasis no more than 49% of
the time when given a choice among 11 adenocarcinomas.
When asked to rank their guesses, the correct diagnosis was
among the top three choices just 76% of the time.
In this paper, we used the largest collection of uniformly
processed primary cancer whole genomes assembled to date to
develop a supervised machine-learning system capable of accu-
rately distinguishing 24 major tumour types based solely on
features that can be derived from DNA sequencing. The accuracy
of the system overall when applied in a cross-validation setting
was 91%, with 20 of the 24 tumour types achieving an F1 score of
0.83 or higher. When the tumour-type predictions were ranked
according to their probability scores, the correct prediction was
found among the top three rankings 98% of the time. When
applied to external validation data sets, the classifier achieved
predictive accuracies of 88% and 83%, respectively, for primary
and metastatic tumours. The modestly reduced accuracy in the
validation sets is likely due to their differing somatic mutation-
calling pipelines, which used different quality-control filters,
genome builds and SNV callers from the specimens in the
training set.
The regional distribution of somatic passenger mutations
across the genome was the single most predictive class of feature,
followed by the distribution of mutation types. The regional
density of somatic mutations is thought to reflect chromatin
accessibility to DNA repair complexes, which in turn relates to
the epigenetic state of the cancer’s cell of origin. The DNN’s
predictive accuracy is therefore largely driven by a cell-of-origin
signal, aided to a lesser extent by signatures of exposure. The
observation that the classifier was able to identify the site of origin
for metastatic and primary tumours with similar accuracy sug-
gests that the cell of origin and exposure signals are already
established in the early cancer (or its precursor cell) and are not
masked by subsequent mutations that occur during tumour
evolution.
Unexpectedly, the distribution of functional mutations
across driver genes and pathways were poor predictors of
tumour type in all but a few tumour types. This surprising
finding may be explained by the observation that there are
relatively few driver events per tumour (mean 4.6 events per
tumour31), and affect a set of common biological pathways
related to the hallmarks of cancer32. This finding may also
explain the observation that automated prediction of tumour
type by exome or gene panel sequencing has so far met with
mixed success (see below).
There was considerable variability in the classification accuracy
among tumour types. In most cases, tumour types that were
frequently confused with each other had biological similarities,
such as related tissues or cells of origin. Technical issues that
could degrade predictive accuracy include uneven sequencing
coverage, low sample purity, inadequate numbers of samples in
the training set and tumour-type heterogeneity. A larger collec-
tion of tumours with WGS would allow us to improve the clas-
sifier accuracy as well as to train the classifier to recognise
clinically significant subtypes of tumours.
There are other ways of identifying the site of origin of a
tumour. In cases in which the tumour type is uncertain, pathol-
ogists frequently apply a series of antibodies to tissue sections to
detect tissue-specific antigens via immunohistochemistry (IHC).
The drawback of IHC is that it requires manual interpretation,
and the decision tree varies according to the differential diag-
nosis3. Furthermore, IHC is known to be confounded by the loss
of antigens in poorly differentiated tumours33. In principle,
tumour differentiation state should not impact the performance
of our classifier because it relies on the distribution of passenger
mutations, most of which are already established at the time of
tumour initiation. Because of the many different grading systems
applied across the PCAWG set, a direct test of this notion is
difficult, but we are reassured that the independent set of
metastases, which frequently represent a higher grade than the
primary, performed as well as the external primary tumour
validation set.
An alternative to IHC is molecular profiling of tumours using
mRNA or miRNA expression, and several commercial systems
are now available to identify the tissue of origin using microarray
or qRT-PCR assays28,34,35. A recent comparative review34 of five
commercial expression-based kits reported overall accuracies
between 76 and 89%; the number of tumour types recognised by
each system ranges from 6 to 47 with accuracy tending to
decrease as the number of discriminated types increases.
Patterns of DNA methylation are also strongly correlated with
the tissue of origin. A recent report36 demonstrated highly
accurate classification of more than 70 central nervous system
tumour types using a Random Forest classifier trained on
methylation array data. Another recent report37 showed that an
immunoprecipitation-based protocol can recover circulating
tumour DNA from patient plasma and accurately distinguish
among three tumour types (lung, pancreatic and AML) based on
methylation patterns.
Previous work in the area of DNA-based tumour-type
identification has used targeted gene panel38 and whole-
exome39–41 sequencing strategies. The targeted gene-based
approach described in Tothill38 is able to discriminate a
handful of tumour types that have distinctive driver gene
profiles, and can identify known therapeutic response bio-
markers, but does not have broader applicability to the problem
of tumour typing. In contrast, the whole-exome sequencing
approaches were reported by Marquard41, Chen39 and Soh40
and each used machine-learning approaches to discriminate
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among 10, 17 and 28 primary sites, respectively, achieving
overall accuracies of 69%, 62% and 78%. Interestingly, all three
papers demonstrated that classifiers built on multiple feature
categories outperformed those built on a single type of feature,
consistent with our findings. We demonstrate here that the
addition of whole-genome-sequencing data substantially
improves discriminative ability over exome-based features. It is
also worth noting that Soh40 was able to achieve good accuracy
using SNVs and CNAs spanning just 50 genes, suggesting that it
may be possible to retain high classifier accuracy while using
mutation ascertainment across a well-chosen set of whole
genomic regions.
In practical terms, whole-genome sequencing and analysis of
cancers are becoming increasingly cost-effective, and there is an
accelerating trend to apply genome sequencing to routine cancer
care in order to identify actionable mutations and to test for the
presence of predictive biomarkers. An example of the trend is the
National Health Service of the United Kingdom, which recently
announced a plan to apply WGS routinely to cancer patients42.
Given the increasing likelihood that many or most cancers will
eventually have genomic profiling, it is attractive to consider the
possibility of simultaneously deriving the cancer type using an
automated computational protocol. This would serve as an
adjunct to histopathological diagnosis, and could also be used as a
quality-control check to flag the occasional misdiagnosis or to
find genetically unusual tumours. More forward-looking is the
prospect of accurately determining the site of origin of circulating
cell-free tumour DNA detected in the plasma using so-called
liquid biopsies43, possibly in conjunction with methylome
analysis36,37. As genome-sequencing technologies continue to
increase in sensitivity and decrease in cost, there are realistic
prospects for blood tests to detect early cancers in high-risk
individuals44. The ability to suggest the site and histological type
of tumours detected in this way would be invaluable for
informing the subsequent diagnostic workup.
In summary, this is the first study to demonstrate the
potential of whole-genome sequencing to distinguish major
cancer types on the basis of somatic mutation patterns alone.
Future studies will focus on improving the classifier perfor-
mance by training with larger numbers of samples, subdividing
tumour types into major molecular subtypes, adding new feature
types and adapting the technique to work with clinical speci-
mens such as those from formalin-fixed, paraffin-embedded
biopsies and cytologies.
Methods
PCAWG training and testing data set. All variant call data were downloaded
from the ICGC Portal (http://dcc.icgc.org/releases/PCAWG/), and all file names
given here are relative to this path. Note that controlled tier access credentials are
required from the ICGC and TCGA projects as described in https://docs.icgc.org/
pcawg/data/. The consensus Somatic SNV and INDEL files (consensus_snv_indel/
final_consensus_snv_indel_passonly_icgc.open.tgz and final_consensus_snv_in-
del_tcga.controlled.tgz) covers 2778 whitelisted samples from 2583 donors. Con-
sensus SV calls from the PCAWG Structural Variation Working Group were
downloaded in VCF format (consensus_sv/final_consensus_sv_vcfs_passonly.icgc.
controlled.tgz and final_consensus_sv_vcfs_passonly.tcga.controlled.tgz). Ploidy
and purity information are from the PCAWG Evolution and Heterogeneity
Working Group (consensus_cnv/consensus.20170217.purity.ploidy.txt.gz) and
driver events were called by the PCAWG Drivers and Functional Interpretation
Group (driver_mutations/TableS3_panorama_driver_mutations_ICGC_samples.
controlled.tsv.gz and TableS3_panorama_driver_mutations_TCGA_samples.con-
trolled.tsv.gz). Tumour histological classifications were reviewed and assigned by
the PCAWG Pathology and Clinical Correlates Working Group (annotation ver-
sion 9, August 2016; clinical_and_histology/pcawg_specimen_histology_Au-
gust2016_v9.xlsx). For model training, we first removed all samples that had been
flagged as exhibiting microsatellite instability (MSI) by the PCAWG Technical
Working Group (msi/MS_analysis.PCAWG_release_v1.RIKEN.xlsx). In a small
number of cases, the same donor contributed both primary and metastatic tumour
specimens to the PCAWG data set. In these cases, we used only the primary
tumour for training and evaluation, except for the case of the small cohort of
myeloproliferative neoplasms (Myeloid-MPN; N= 55 samples), for which multiple
primary samples were available. In this case, we used up to two samples per donor
and partitioned the training and testing sets to avoid having the same donor appear
more than once in any training/testing set trial (see Supplementary Data 1 for the
complete list of tumour specimens).
Independent validation data set: primary and metastatic tumours. To inde-
pendently validate the neural network-based classifier, we assembled several sets of
tumours that had been subject to whole-genome sequencing outside of PCAWG
(Supplementary Data 4).
The primary tumour validation data set consisted of 1236 primary tumours
contributed by colleagues participating in the PCAWG Mutational Signatures
Working Group and described in ref. 16. These represent 12 tumour types
overlapping with PCAWG types collected from a variety of published studies, non-
PCAWG donors submitted to the ICGC data portal (http://dcc.icrg.org) and
donors present in the COSMIC database (http://cancer.sanger.ac.uk/cosmic). These
independent primaries were supplemented using WGS data from 200 advanced
primary pancreatic ductal adenocarcinomas (Panc-AdenoCA) derived from the
COMPASS Trial25 and used with the gracious permission of Dr. Steven Gallinger.
In all, the primary tumour validation set contained 1436 primary tumour samples
across 12 tumour types. Only tumour types with 10 or more representatives were
used for testing.
The metastatic tumour validation data set was derived from SNV calls on
2028 metastatic tumours across 16 tumour types, provided by the Hartwig Medical
Foundation (HMF data set). They are a subset of 2090 total samples provided
by Dr. Edwin Cuppen with matched PCAWG histology subtypes and are
described in Supplementary Data 4 and Priestley26. We supplemented this set with
92 metastatic pancreatic ductal adenocarcinomas to the liver from the COMPASS
Trial, for a total of 2120 metastatic tumours. As for the primaries, only tumour
types with ten or more representatives were tested.
Although the sequencing technologies and genome coverage are comparable
among the PCAWG training set and the independent validation data sets, a
mixture of different human genome builds, alignment algorithms and SNV calling
algorithms were used for the validation data sets. We did not attempt to recall the
SNVs, but did lift the genome coordinates of samples that had been aligned to
other genome builds to hg19 by CrossMap (Version 0.2.5).
Human studies approval. All patients who donated to the PCAWG, COMPASS
and HMF data sets consented to international data sharing and secondary analysis
of their genomes25,26,45. Permission to reanalyse these data was granted by the
University of Toronto’s Research Ethics Board.
Somatic mutation feature sets. Mutational-type features are based on all point
substitutions (single-nucleotide variations, SNVs). For each sample, SNVs are
categorised across the six possible single-nucleotide changes (A– > C, A– > G, A– >
T, C– > A, C– > G and C–T), the 48 possible nucleotide changes plus their 5′ or
3′ flanking base and the 96 possible nucleotide changes plus both flanking
nucleotides. This generates 150 mutational-type features in total. The counts in
each category are then normalised to the total number of SNVs in the sample.
Mutational distribution features are the number of SNVs, small indels,
structural variation (SV) breakpoints and somatic copy-number variations (CNVs)
in each 1-megabase bin across the genome. The total number of SNV, indel and SV
counts in each bin were normalised to the total number of the corresponding
mutational events across the genome. In addition, we generated the following
features: (1) the total numbers of each type of mutational event per genome; (2) the
number of each type of mutational event per chromosome, normalised by
chromosome length; (3) sample purity values; (4) sample ploidy. In total, there are
2897 SNV+ indel, 2826 CNV and 2929 SV features. For the initial selection of
feature types, we tested all mutational distribution features. However, the final
neural network used SNV features only.
Driver gene and pathway features were derived from the driver event list
generated by the PCAWG Drivers and Functional Interpretation Working
Group18. This list contains driver events in coding genes, as well as events that
affect miRNA and lncRNAs. We generated a boolean matrix from the list in which
each row is a tumour sample and each column is a driver event. To mutations to
pathways, we selected any non-synonymous SNV affecting a gene in a pathway,
regardless of its putative driver status. These SNVs were then assigned to 1865
pathways from the Reactome resource (http://www.reactome.org, version 58)46.
A pathway feature was scored as positive if it contained at least one driver gene.
Because a gene may be contained within more than one pathway, it is possible for a
single driver gene event to generate two or more positive pathway features.
Machine-learning procedure—Random Forest. For each of the 24 cancer types
selected from the PCAWG sample set, we first used Random Forest model to train
classifiers for each cancer type on each of the feature categories described in the
above section. The data sets were z-score normalised across the samples before
training. We used nested cross-validation to train and test the performance of the
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classifiers. In the outer loop, the data set was divided into four folds, and each fold
was later used as an independent testing set. In the inner loop, the training portion
of the data set was split into three folds, and each fold was used as validation data
set to fine-tune the hyperparameters. In the inner loop, we first used a chi-squared
test to filter out non-informative (V coefficient equals to 0) features. Then we tuned
two hyperparameters for the Random Forest model to achieve the highest cross-
validation F1 score. The two hyperparameters were the sample size for positive
versus negative classes and the number of trees. We used the default R random-
Forest package parameter settings to sample the square root of the number of
features at each split of the tree. The code was written in R (version 3.3.0). The
main packages used were MLR (version 2.11) and randomForest (4.6–12) in
training the model.
Machine-learning procedure—Neural Network. We ultimately used a fully
connected, feed-forward neural network for the classification of the 24 cancer types
based on SNV type and mutational distribution alone. The network had a softmax
output, which can be interpreted as a probability distribution of the 24 types. The
predicted tumour type was selected by taking the type with the greatest softmax
probability.
We used a Bayesian optimisation approach to select hyperparameters47.
Prior to training, data from PCAWG were split into training, validation and
test sets ten times to create ten different partitions over the full data set. For
each of the ten partitions, hyperparameters were selected by optimising
performance on the validation data for that partition. We used the
‘gp_minimize’ function from the scikit-optimise 0.5.2 python library48 to select
the following hyperparameters: learning rate for Adam, L2-regularisation
penalty (otherwise known as weight decay), dropout rate49, the number of
hidden layers, the number of neurons per hidden layer and activation function.
Each model was trained using Adam50 with a batch size of 32 for 50 epochs. All
hyperparameters of Adam other than learning rate were set to the default
values specified in the original paper50. Bias values were initialised as 0, and all
other network weights were initialised using a glorot uniform distribution51.
The model was evaluated with 200 hyperparameter combinations (i.e., 200 calls
to ‘gp_minimize’ were made). Briefly, ‘gp_minimize’ approximates a function
of model performance based on the hyperparameters with a Guassian Process.
For each function call to ‘gp_minimize’, the performance on the current set of
hyperparameters is evaluated by training the neural network, and assessing
accuracy on the validation set. Based on this accuracy, the Guassian Process is
updated, and a new set of hyperparameters is chosen by optimising an
acquisition function. We used expected improvement as the acquisition
function. After hyperparameter optimisation, model performance was assessed
independently on the corresponding test set for that split. Supplementary
Table 1 describes the settings for each of the folds for these hyperparameters.
In order to compare the accuracy of these models with models trained on
different feature sets, the procedure above was repeated using driver genes/
pathways as input, and again by appending the driver genes/pathway features to
the SNV features used above. The final hyperparameter values and model
accuracies for each of the trained models are described in Supplementary Data 6.
Each model was implemented and trained in Tensorflow 1.10.052 and Keras
2.1.553. All code was written in Python 3.6.
Definitions of accuracy metrics. To measure the performance of the classifiers,
we use the conventional definitions of recall, precision, F1 score and accuracy. In
the descriptions below, we use the abbreviations TP (true positive), TN (true
negative), FP (false positive) and FN (false negative) to describe correct and
incorrect assignments of an unknown tumour to a predicted type, as described by
this confusion matrix (Table 3):
Recall: The proportion of samples of a particular histopathological type that are
correctly assigned to that type:
Recall ¼ TP= TPþ FNð Þ: ð1Þ
Precision: The proportion of samples assigned to a particular type that are truly
that type:
Precision ¼ TP= TPþ FPð Þ: ð2Þ
F1 Score: The harmonic mean of recall and precision:
F1 ¼ 2 recall  precisionð Þ= recallþ precisionð Þ: ð3Þ
Accuracy: The proportion of correct assignments. We use this metric
only when summarising the performance of the classifier across all 24 tumour
types:
Accuracy ¼ TPþ TNð Þ= TPþ FPþ TNþ FNð Þ ¼ correct assignments=total samples:
ð4Þ
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data sets underpinning the analyses in the paper are detailed in Supplementary
Table 2. Aligned sequencing data, as well as somatic and germline variant calls from
PCAWG tumours, including single-nucleotide variants, indels, copy-number alterations
and structural variants, are available for download at https://dcc.icgc.org/releases/
PCAWG. Additional information on accessing the data, including raw read files, can be
found at https://docs.icgc.org/pcawg/data/. In accordance with the data access policies of
the ICGC and TCGA projects, most molecular, clinical and specimen data are in an open
tier that does not require access approval. To access potentially identification
information, such as germline alleles and the underlying sequencing data, researchers will
need to apply to the TCGA Data Access Committee (DAC) via dbGaP (https://dbgap.
ncbi.nlm.nih.gov/aa/wga.cgi?page= login) for access to the TCGA portion of the data
set, and to the ICGC Data Access Compliance Office (DACO; http://icgc.org/daco) for
the ICGC portion. In addition, to access somatic single-nucleotide variants derived from
TCGA donors, researchers will also need to obtain dbGaP authorisation. In addition, the
analyses in this paper used a number of data sets that were derived from the raw
sequencing data and variant calls (Supplementary Table 2). The individual data sets are
available at Synapse (https://www.synapse.org/), and are denoted with synXXXXX
accession numbers (listed under Synapse ID); all these data sets are also mirrored at
https://dcc.icgc.org, with full links, file names, accession numbers and descriptions
detailed in Supplementary Table 2. The data sets encompass harmonised tumour
histopathology annotations using a standardised hierarchical ontology (syn1038916);
driver mutations for each patient from their cancer genome spanning all classes of
variants, and coding versus non-coding drivers (syn11639581); clinical data from each
patient, including demographics, tumour stage and vital status (syn10389158); inferred
purity and ploidy values for each tumour sample (syn8272483). The independent
metastatic tumour-independent validation data set generated by the Hartwig Medical
Foundation is described in the paper Pan-cancer whole-genome analyses of metastatic
solid tumours. Nature. 2019 Oct 23. https://doi.org/10.1038/s41586-019-1689-y. Data are
available by application to https://www.hartwigmedicalfoundation.nl/en/appyling-for-
data/. The remaining metastatic and primary tumour variant call sets used for
independent validation have been published and their availability is described in the
publications listed in Supplementary Data 4.
Code availability
The code developed for training and testing the classifier, along with documentation and
trained models for the 24 tumour types are available from GitHub at https://github.com/
ICGC-TCGA-PanCancer/TumorType-WGS.git. The core computational pipelines used
by the PCAWG Consortium for alignment, quality control and variant calling are
available to the public at https://dockstore.org/search?search=pcawg under the GNU
General Public License v3.0, which allows for reuse and distribution. The code is
distributed under the Apache Version 2.0 Open Source license (https://www.apache.org/
licenses/LICENSE-2.0).
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